These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 12637944

  • 1. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.
    Wen SF, Mahavni V, Quijano E, Shinoda J, Grace M, Musco-Hobkinson ML, Yang TY, Chen Y, Runnenbaum I, Horowitz J, Maneval D, Hutchins B, Buller R.
    Cancer Gene Ther; 2003 Mar; 10(3):224-38. PubMed ID: 12637944
    [Abstract] [Full Text] [Related]

  • 2. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M.
    Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
    [Abstract] [Full Text] [Related]

  • 3. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
    Randrianarison V, Marot D, Foray N, Cabannes J, Méret V, Connault E, Vitrat N, Opolon P, Perricaudet M, Feunteun J.
    Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
    [Abstract] [Full Text] [Related]

  • 4. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.
    Kim J, Hwang ES, Kim JS, You EH, Lee SH, Lee JH.
    Cancer Gene Ther; 1999 Oct; 6(2):172-8. PubMed ID: 10195884
    [Abstract] [Full Text] [Related]

  • 5. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J, Sato S, Shimada M, Kanamori Y, Itamochi H, Terakawa N.
    Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
    [Abstract] [Full Text] [Related]

  • 6. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
    Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R.
    Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
    [Abstract] [Full Text] [Related]

  • 7. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y, Tokino T.
    Clin Cancer Res; 2009 Jun 01; 15(11):3725-32. PubMed ID: 19458054
    [Abstract] [Full Text] [Related]

  • 8. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J.
    Curr Opin Mol Ther; 1999 Aug 01; 1(4):500-9. PubMed ID: 11713766
    [Abstract] [Full Text] [Related]

  • 9. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro.
    Roy I, Holle L, Song W, Holle E, Wagner T, Yu X.
    Anticancer Res; 2002 Aug 01; 22(6A):3185-9. PubMed ID: 12530063
    [Abstract] [Full Text] [Related]

  • 10. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL, Perruchoud AP, Reuter J, Bolliger C, Herrmann R, Rochlitz C.
    Cancer Gene Ther; 2000 Sep 01; 7(9):1215-9. PubMed ID: 11023193
    [Abstract] [Full Text] [Related]

  • 11. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.
    Anderson SC, Johnson DE, Harris MP, Engler H, Hancock W, Huang WM, Wills KN, Gregory RJ, Sutjipto S, Wen SF, Lofgren S, Shepard HM, Maneval DC.
    Clin Cancer Res; 1998 Jul 01; 4(7):1649-59. PubMed ID: 9676839
    [Abstract] [Full Text] [Related]

  • 12. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
    Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK.
    Cancer Gene Ther; 2006 Aug 01; 13(8):806-14. PubMed ID: 16628227
    [Abstract] [Full Text] [Related]

  • 13. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT, Levenback C, Gershenson DM.
    Gynecol Oncol; 2004 Aug 01; 94(2):442-8. PubMed ID: 15297186
    [Abstract] [Full Text] [Related]

  • 14. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
    Grace MJ, Xie L, Musco ML, Cui S, Gurnani M, DiGiacomo R, Chang A, Indelicato S, Syed J, Johnson R, Nielsen LL.
    Am J Pathol; 1999 Dec 01; 155(6):1869-78. PubMed ID: 10595917
    [Abstract] [Full Text] [Related]

  • 15. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR, Wang-Gohrke S, Köhler T, Kreienberg R, Runnebaum IB.
    Cancer Gene Ther; 2004 Aug 01; 11(8):547-54. PubMed ID: 15153938
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.
    Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang Z, Zhao H.
    J Oral Maxillofac Surg; 2009 May 01; 67(5):1074-82. PubMed ID: 19375021
    [Abstract] [Full Text] [Related]

  • 17. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
    Wolf JK, Mills GB, Bazzet L, Bast RC, Roth JA, Gershenson DM.
    Gynecol Oncol; 1999 Nov 01; 75(2):261-6. PubMed ID: 10525383
    [Abstract] [Full Text] [Related]

  • 18. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
    Collinet P, Vereecque R, Sabban F, Vinatier D, Leblanc E, Narducci F, Querleu D, Quesnel B.
    J Obstet Gynaecol Res; 2006 Oct 01; 32(5):449-53. PubMed ID: 16984510
    [Abstract] [Full Text] [Related]

  • 19. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma.
    Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ, Su X, Li DM, Xu G, Xu B, Lu YY.
    J Clin Oncol; 2009 Feb 10; 27(5):799-804. PubMed ID: 19103729
    [Abstract] [Full Text] [Related]

  • 20. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression.
    Kralj M, Husnjak K, Körbler T, Pavelić J.
    Cancer Gene Ther; 2003 Jun 10; 10(6):457-67. PubMed ID: 12768191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.